作者
Rie Nishikawa‐Shimono,Motoi Kuwabara,Sho Fujisaki,Daisuke Matsuda,Mayumi Endo,M. Kamitani,Aya Futamura,Yusaku Nomura,Toru Yamaguchi-Sasaki,Tetsuya Yabuuchi,Chitose Yamaguchi,Nozomi Tanaka-Yamamoto,Shunya Satake,Kumi Abe-Sato,Kosuke Funayama,Mayumi Sakata,Shinji Takahashi,Koga Hirano,Takuya Fukunaga,Yoriko Uozumi,Sayaka Kato,Yunoshin Tamura,Tomoaki Nakamori,Masashi Mima,Chiemi Mishima-Tsumagari,Dai Nozawa,Yudai Imai,Taiji Asami
摘要
Matrix metalloproteinase-9 (MMP-9) is a secreted zinc-dependent endopeptidase that degrades the extracellular matrix and basement membrane of neurons, and then contributes to synaptic plasticity by remodeling the extracellular matrix. Inhibition of MMP-9 activity has therapeutic potential for neurodegenerative diseases such as fragile X syndrome. This paper reports the molecular design, synthesis, and in vitro studies of novel indole derivatives as inhibitors of proMMP-9 activation. High-throughput screening (HTS) of our internal compound library and subsequent merging of hit compounds 1 and 2 provided compound 4 as a bona-fide lead. X-ray structure-based design and subsequent lead optimization led to the discovery of compound 33, a highly potent and selective inhibitor of proMMP-9 activation.